Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Cash (2019 - 2025)

Eton Pharmaceuticals' Change in Cash history spans 7 years, with the latest figure at $11.7 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 357.42% year-over-year to $11.7 million; the TTM value through Sep 2025 reached $16.9 million, up 1032.01%, while the annual FY2024 figure was -$6.5 million, 226.93% down from the prior year.
  • Change in Cash for Q3 2025 was $11.7 million at Eton Pharmaceuticals, up from $8.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $11.7 million in Q3 2025 and bottomed at -$8.3 million in Q4 2021.
  • The 5-year median for Change in Cash is $823000.0 (2022), against an average of $832947.4.
  • The largest annual shift saw Change in Cash skyrocketed 1319.33% in 2021 before it plummeted 680.79% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$8.3 million in 2021, then skyrocketed by 135.25% to $2.9 million in 2022, then crashed by 123.3% to -$682000.0 in 2023, then tumbled by 680.79% to -$5.3 million in 2024, then surged by 320.51% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Change in Cash are $11.7 million (Q3 2025), $8.0 million (Q2 2025), and $2.5 million (Q1 2025).